Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial

Michael Friedlander, Val Gebski, Emma Gibbs, Lucy Davies, Ralph Bloomfield, Felix Hilpert, Lari B. Wenzel, Daniel Eek, Manuel Rodrigues, Andrew Clamp, Richard T. Penson, Diane Provencher, Jacob Korach, Tomasz Huzarski, Laura Vidal, Vanda Salutari, Clare Scott, Maria Ornella Nicoletto, Kenji Tamura, David EspinozaFlorence Joly, Eric Pujade-Lauraine

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial'. Together they form a unique fingerprint.

Medicine & Life Sciences